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Abstract
Background: The treatment of methamphetamine dependence is a continuing global health problem. Agonist
type pharmacotherapies have been used successfully to treat opioid and nicotine dependence and are being
studied for the treatment of methamphetamine dependence. One potential candidate is lisdexamfetamine, a
pro-drug for dexamphetamine, which has a longer lasting therapeutic action with a lowered abuse potential.
The purpose of this study is to determine the safety of lisdexamfetamine in this population at doses higher than
those currently approved for attention deficit hyperactivity disorder or binge eating disorder.
Methods/design: This is a phase 2 dose escalation study of lisdexamfetamine for the treatment of methamphetamine
dependence. Twenty individuals seeking treatment for methamphetamine dependence will be recruited at two
Australian drug and alcohol services. All participants will undergo a single-blinded ascending-descending dose regime of
100 to 250 mg lisdexamfetamine, dispensed daily on site, over an 8-week period. Participants will be offered counselling
as standard care. For the primary objectives the outcome variables will be adverse events monitoring, drug tolerability
and regimen completion. Secondary outcomes will be changes in methamphetamine use, craving, withdrawal, severity
of dependence, risk behaviour and other substance use. Medication acceptability, potential for non-prescription use,
adherence and changes in neurocognition will also be measured.
Discussion: Determining the safety of lisdexamfetamine will enable further research to develop pharmacotherapies for
the treatment of methamphetamine dependence.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12615000391572 Registered 28th April 2015.
Keywords: Methamphetamine, Study protocol, Lisdexamfetamine, Pharmacotherapy, Dose-finding, Stimulant use disorder
Background
Background
Amphetamine type stimulants, including methampheta-
mine, present a global public health concern. The second
most commonly used illicit drug worldwide, approximately
34 million people aged 15–64 (range 14–56 million) were
estimated to be using amphetamine type stimulants in 2010
[1] with 17 million people (range 14–21 million) estimated
to have dependence [2]. Problems from stimulant use in
Australia are largely related to methamphetamine, and
include psychosis (often requiring hospital admission),
dependence, injecting-related risks, high-risk sexual
practices, psychological disturbances, and acute cardio-
vascular and cerebrovascular events [3]. The current
standard care for methamphetamine dependence com-
prises psychosocial interventions, which shows modest
rates of induction and retention with many effects lost
at follow-up [4, 5].
Agonist-type pharmacotherapies are candidates to
improve treatment outcomes for methamphetamine de-
pendence. By mimicking the pharmacodynamic effects
of methamphetamine [6], agonists may ameliorate with-
drawal and cravings, attenuate the positive effects of
methamphetamine use, enable use reduction or abstinence
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and/or increase engagement with treatment [7]. Additional
harm reduction may be achieved by replacing illegal drug
use with a legal, orally administered and regulated alter-
native. Agonist-type pharmacotherapies have successfully
promoted use reduction and treatment retention in opioid
dependence [8] and smoking abstinence for nicotine
dependence [9]. Emerging evidence suggests that dex-
amphetamine may be effective in reducing cocaine use
among heroin-maintained individuals [10] and a statis-
tical trend in improving sustained cocaine abstinence
has been observed in trials of dexamphetamine, moda-
fanil and bupropion [11, 12].
Both immediate and extended release forms of dexam-
phetamine have been trialled as agonist-type pharmaco-
therapies for methamphetamine dependence [13–16].
The active component dexamphetamine induces neuro-
transmitter release with a similar pattern to metham-
phetamine. Randomized controlled trials using 60 to
110 mg of dexamphetamine have shown a statistically sig-
nificant decrease in amphetamine withdrawal (g ~ 0.57 to
0.62 [13, 14]) and craving (g ~ 0.59 [14]) and an increase
in treatment retention (g ~ 0.72 [13, 14]). Although there
was a significant decrease in methamphetamine use from
baseline, the trials appear insufficiently powered to elicit a
difference from placebo.
Methamphetamine dependence research is currently lim-
ited by a low number of published, randomized controlled
trials with adequate sample size, duration and follow-up
[17]. More targeted therapy should also be considered, with
increased stimulant dependence at baseline, longer dosing
intervals, higher doses and longer duration of treatment
correlating with better clinical outcomes for psychostimu-
lant dependence [7].
Lisdexamfetamine dimesylate (LDX), a dexamphetamine
pro-drug, has been developed for the treatment of atten-
tion deficit hyperactivity disorder and binge eating dis-
order [18]. Once ingested, LDX undergoes rate-limited
hydrolysis by enzymes within red blood cells to release
l-lysine and dexamphetamine [19]. The in vivo and rate
limited conversion of LDX provides longer lasting
therapeutic action with pre-clinical studies showing a
slower onset and longer lasting dopamine release in rat
striatum compared to similar agonist formulations, im-
mediate release dexamphetamine and methylphenidate
[20, 21]. Pharmacokinetic studies have shown longer time
to peak, lower maximal concentration and longer duration
of action compared to immediate release dexamphetamine
[22]. The pro-drug also benefits from a reduced diversion
or abuse liability with the kinetics of dexamphetamine
remaining consistent between intranasal, intravenous or
oral administration [23, 24]. In clinical studies LDX has
displayed a lower subjective drug liking by stimulant users
when compared to immediate release dexamphetamine
and methylphenidate [24, 25].
Rationale for study
LDX has the potential to improve treatment outcomes
for methamphetamine dependence, however there have
been no published trials addressing this question.
Doses of 100 to 250 mg LDX may be required to
match the 60 to110mg used in trials of dexampheta-
mine for methamphetamine dependence. These doses
are higher than the 70 mg LDX currently approved for
attention deficit hyperactivity disorder and binge eat-
ing disorder. In order to inform the design of phase 3
trials on the efficacy of LDX as a treatment for meth-
amphetamine dependence, the safety of LDX in this
population at the required therapeutic doses needs to
be established.
The four most common side effects noted by partici-
pants in clinical trials of LDX are decreased appetite (27%),
insomnia (27%), dry mouth (26%) diarrhea/nausea (both
7%) in adults with ADHD [18] and dry mouth (36%), head-
ache (14%), insomnia (14%) and decreased appetite (12%)
in adults with binge eating disorder [26]. LDX is contrain-
dicated in persons with known allergy and with concurrent
or use within the previous 14 days of monoamine oxidase
inhibitors (MAOIs) [18]. There are also warnings and
precautions for serious cardiovascular reactions, blood
pressure and heart increases, psychiatric adverse reac-
tions and peripheral vasculopathy (including Raynaud’s
phenomenon). On this basis, known contraindications,
pre-existing cardiovascular disease and peripheral vas-
culopathy will be exclusion criteria for the trial, and
measurement tools specific to blood pressure, heart
rate, psychiatric symptoms, weight and insomnia will
be administered (see Table 1). Other adverse effects




The study is a phase 2, single group, outpatient study
with a study period of 14 weeks, inclusive of screening
and follow up. Screening will occur over 2 weeks
(weeks −2 and −1), and eligible participants commenced
on the escalation/de-escalation phase (week 1). Escalation
of LDX will occur over 4 weeks, beginning at 100 mg/day,
with weekly increases of 50 mg to a maximum 250 mg/
day. After 2 weeks at 250 mg/day LDX, the dose of LDX
will be reduced weekly by 50 mg/day, ceasing after 1 week
at 100 mg/day. A follow up study visit will occur in week
12, 4 weeks after cessation of study drug. The study aims
to enrol a sample of twenty participants who are seeking
treatment for methamphetamine dependence. A diagram-
matic overview of the study is given in Fig. 1. The proto-
col has been designed in accordance with CONSORT
SPIRIT guidelines [27].
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Table 1 Schedule of enrolment, intervention and assessments based on SPIRIT 2013 guidelines [27]





Medical & Psychiatric History ●
Self-reported drug use ●
Concomitant medications ●
Intervention
Treatment as usual (counselling) offered weekly
Dose of Lisdexamfetamine (mg)-dispensed daily 100 150 200 250 250 200 150 100 End FU
Baseline Measures
MOCA, AUDIT, WTAR, Wender Utah Scale ●
Primary Outcomes
Brief Psychiatric Scale: psychosis & hostility items ● ● ● ● ● ● ● ● ● ●
Vital Signsa (Blood pressure, pulse, temperature) ● ● ●t ●t ●t ●t ● ● ● ● ●
Insomnia Severity Index ● ● ● ● ● ●
Patient Health Questionnaire 15 ● ● ● ●
Patient Health Questionnaire 9 ● ● ● ● ● ●
Generalized Anxiety Disorder 7 ● ● ● ● ● ●
Weight (in kilograms) ● ● ● ● ●
Adverse Events Log ● ● ● ● ● ● ● ● ● ●
Electrocardiogram ● ● ●
TSQM-side-effects item ● ● ● ● ● ● ● ● ●
Proportion completing dose escalation phase ●
Secondary Outcomes
Substance Use TLFB-MA (Days Used) ● ● ● ● ● ● ● ● ● ● ●
Urine Drug Screen (positive MA) ●d ● ● ● ● ● ● ● ● ● ●
Substance Use TLFB-MA (Days Used) ● ● ● ● ● ● ● ● ● ●
Urine Drug Screenc ●d ● ● ● ● ● ● ● ● ● ●
TSQM-effectiveness item ● ● ● ● ● ● ● ● ● ●
Visual Analogue Scale for MA craving ●t ●t ●t ●t ●t ● ● ● ● ●
Amphetamine Withdrawal Questionnaire ●t ●t ●t ●t ●t ● ● ● ● ●
Severity of Dependence Scale ● ● ●
Adapted Opiate Treatment Index (HIV & crime scales) ● ● ●
TSQM-convenience & global satisfaction items ● ● ● ● ● ● ● ● ● ●
Proportion discontinuing once enrolled ● ● ● ● ● ● ● ●
Price would Pay ●b ●b ●b ●b ●b
Similarity to MA Visual Analogue Scale ●b ●b ●b ●b ●b
Drug Effects Questionnaire 5 ●b ●b ●b ●b ●b
Acute Subjective Response to Substances ●b ●b ●b ●b ●b
Trail-making Test ●t ●t ●t ●t ●t ●
Rey Auditory Verbal Learning Task ●t ●t ●t ●t ●t ●
Digit-span sequencing ●t ●t ●t ●t ●t ●
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Study objectives
The study’s primary objectives are to describe the safety,
tolerability and regimen completion of ascending doses
of LDX in adults with methamphetamine dependence.
Secondary outcomes include changes in methampheta-
mine use, craving, withdrawal, severity of dependence, risk
behaviour and in other substance use. Medication accept-
ability, potential for non-prescription use, adherence and
changes in neurocognition will also be measured.
Inclusion criteria
Participants in the trial are aged at least 18 years or
over who fulfil ICD10 criteria [28] for methampheta-
mine dependence and have ≥2 years of problematic
methamphetamine use (self-reported), for which they
are currently seeking treatment. Each participant must
have a self-reported methamphetamine use of ≥14 days
in the 28 days prior to consenting. A urine specimen is
obtained weekly for 2 weeks prior to the commencement
of study drug, and screened to verify methamphetamine
use. Participants must be willing and able to comply with
the requirements of the study and be able to provide
written, informed consent.
Exclusion criteria
Exclusion criteria are: use of dexamphetamine in the
previous 4 weeks; sensitivity or previous adverse reaction
to LDX; or current use of medications that could interact
Table 1 Schedule of enrolment, intervention and assessments based on SPIRIT 2013 guidelines [27] (Continued)
Flankers Test with no-go ● ● ● ●
Digit Symbol Substitution ● ● ● ●
Rapid Information Processing ● ● ● ●
Abbreviations: ttimed trough/peak measurements prior to study drug administration/4 h post, TSQM Treatment Satisfaction Questionnaire for Medications, MOCA
Montreal Cognitive Assessment, AUDIT Alcohol Use Disorder Identification Test, WTAR Wechsler Test of Adult Reading, MA methamphetamine, TLFB Time-Line
Follow Back questionnaire
avital signs measured daily
bMeasurement taken 4 h post study drug administration
cUrine drug screen for benzodiazepines, cannabis, cocaine, methadone, morphine/heroin and oxycodone
dTwo urines positive for methamphetamine required for eligibility
Fig. 1 Study flow diagram
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with LDX (venlafaxine, desvenlafaxine, monoamine oxidase
inhibitors (MAOI); MAOI use in the previous 14 days, a
history of moderate to severe hypertension (well-controlled
mild to moderate hypertension on a single antihypertensive
agent permitted), severe and symptomatic peripheral vas-
cular disease or Raynaud’s phenomenon; significant prior
or symptomatic cardiovascular disease; glaucoma; hyper-
thyroidism; phaeochromocytoma; motor and phonic tics;
Tourette’s syndrome; unstable alcohol or other substance
use as assessed by the principal investigator; high suicide
risk; voicing suicidal ideation; active psychosis (past history
of psychosis permitted on review of a psychiatrist); severe
agitation and severe cognitive impairment. Women who
are lactating, pregnant or of childbearing potential who are
not willing to avoid becoming pregnant during the study
will also be excluded.
Identification of participants and informed consent
Initial recruitment is made through clients registered
with stimulant treatment programs at each site. Ethics
Committee-approved print media containing poster and
flyer displays are displayed at each site targeting the sam-
ple population including other drug and alcohol services,
community/NGOs and local general practices surgeries. If
necessary, web-based advertising may be used, including
promotion via the stimulant treatment program’s estab-
lished social media pages. Screening visits are arranged
upon approach by interested individuals who satisfy pre-
screening assessment of basic inclusion and exclusion
criteria.
At the screening visit, the principal investigators at each
site (specialists in addiction medicine) assess the eligibility
of potential participants. The trial is explained verbally
and in written form including the risks and burdens of
participating before written consent is obtained. Screening
involves a medical and substance use history as well as a
physical and mental state examination, electrocardiogram
(ECG) and urinary human chorionic gonadotropin (hCG)
where applicable to verify that the individual meets the
eligibility criteria. Two urine drug screens, at least a week
apart, are used to confirm methamphetamine use.
Intervention
The LDX dosing period is up to 8 weeks and consists of
daily, supervised outpatient oral dose administration at
the participants’ respective site. Dose escalation and de-
escalation range from 100 mg per day to a maximum
250 mg per day, with changes weekly to allow for
achievement of steady state [29]. Both the participants
and drug administration personnel are blinded to date,
amount and direction of dose change. To achieve this,
the dose comprises 5 identical size 0 capsules each con-
taining either 50 mg LDX or placebo according to the
dose escalation phase.
Additionally, participants are offered weekly counselling
with trained and supervised counsellors at the Stimulant
Treatment Programs as current standard of care for
methamphetamine dependence, though attendance is
not mandatory.
Safety and discontinuation
Specific adverse events resulting in participant discontinu-
ation are: pregnancy checked through monthly urinary
hCG tests where applicable; clinically significant hyper-
tension (two consecutive readings of systolic blood pres-
sure >160 mmHg or diastolic blood pressure >100 mmHg
within an hour); persistent tachycardia (>120 beats per
minute for >60 min) or clinically significant psychotic
symptoms (as assessed by the principal investigator). Add-
itional unscheduled visits occur if there is any concern re-
garding possible toxicity. Further reasons for participant
withdrawal are the observed diversion of study drug, with-
drawal of consent, missing three or more doses in a 7 day
period or missing more than one extended data collection
visit. An independent data safety and monitoring board
has been established to ensure adequate safety outcomes
and management of the study drug for the continuation of
the study. It will first meet after 5 participants have com-
menced the study drug and completed up to the end of
the dose escalation period (or discontinued prior) and
then twice yearly. Any adverse effects experienced by par-
ticipants will be treated by the study team, or referred to a
specialist as required.
Assessment schedule
Baseline assessments and demographic data are estab-
lished in the screening visit or before LDX dispensing on
the first day of the LDX intervention. Baseline substance
use history is recorded, and the Alcohol Use Disorder
Identification Tool (AUDIT) used to establish alcohol
use patterns [30]. During the 8-week dosing period, daily
assessment of vital signs and the recording of treatment
emergent adverse events will be undertaken at drug dis-
pensing. In weeks 1–4, one extended visit per week occurs
for detailed data collection concerning the safety and effi-
cacy outcomes. Selected timed assessments (as outlined in
Table 1) are conducted pre-dose dispensing (trough level,
equivalent to LDX steady state) and four hours post dos-
ing for peak levels [31]. In the follow up period 4 weeks
after the final dose, an additional extended visit will assess
the same safety and efficacy outcomes measured in the
dose-escalation period. The participant is reimbursed for
extended visits with the equivalent of $80 in a super-
market voucher. Assessment raters will be trained and
supervised by the study psychologist (RB), an experienced
professor of psychology, and tests will be administered
using standardised scripts.
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Data collection
Primary outcomes
Treatment emergent adverse events (TEAEs) and vital
signs (blood pressure, pulse rate, respiratory rate and
temperature) are recorded daily for the 8-week dosing
period. In weeks 1–4, at each data collection visit, vital
signs are recorded at trough and peak times. An ECG is
performed at weeks 2 and 4, and weight in kilograms
measured at week 4 and at follow-up. Differences in
symptoms of psychosis and hostility are obtained using
the psychosis and hostility items of the Brief Psychiatric
Rating Scale [32], changes in sleep quality measured using
the Insomnia Severity Index [33] and changes in somatic
symptoms, depression and anxiety measured with the
Patient Health Questionnaire 15 [34], Patient Health
Questionnaire 9 [35] and the Generalized Anxiety Disorder
7 [36] questionnaire respectively.
Tolerability of LDX is measured by the Treatment
Satisfaction Questionnaire for Medications (TSQM) side
effects item [37]. Completion rates are calculated by the
proportion of participants completing escalation to steady-
state of 250 mg at week 4.
Secondary objectives
Change in methamphetamine use is recorded with the
substance use Timeline Follow-back (TLFB) interview
[38] and urine drug testing. Urine screening for
amphetamine-type substances is initially determined by
immunoassay (cut-off of 300 ng/ml), before confirmation
of drug type (methamphetamine, amphetamine or other)
using gas chromatography-mass spectroscopy (cut-off of
150 ng/ml) [39]. Change in use of other substances of
concern is also assessed by the TLFB interview, with
urine screening to Australian Standard ASNZS4308
[39] for benzodiazepines, cannabis, cocaine, methadone,
morphine/heroin and oxycodone. Change in risk behav-
iour is assessed through the Opiate Treatment Index
Injecting and Crime risk questionnaires [40]. Craving and
withdrawal symptoms are assessed with a visual analogue
scale for craving [41] and the Amphetamine Withdrawal
Questionnaire [42] at all data collection visits, including
peak and trough times during the extended visits. Severity
of dependence to methamphetamine is assessed with the
Severity of Dependence Scale [43]. Participant rating of
dose adequacy is assessed using the Treatment Satisfaction
Questionnaire for Medication (TSQM) effectiveness item
[37]. Acceptability of the study drug is assessed using
TSQM convenience and global satisfaction items [37].
Potential for non-prescription use (sometimes referred
to as abuse liability) is assessed using the Drug Effects
Questionnaire [44], the Acute Subjective Response to
Substances questionnaire, asking participants what price
they would pay for the drug on the street and using a
visual analogue scale for participants to rate study drug
similarity to methamphetamine [45]. The frequency of
the instruments used to assess secondary objectives is
outlined in Table 1.
Neuropsychological measures taken at baseline are the
Montreal Cognitive Assessment (MoCA) [46] and the
Wechsler Test of Adult Reading (WTAR) [47]. The Wender
Utah scale is used to screen for the presence of co-existing
Attention-Deficit Hyperactivity Disorder [48]. Two separate
batteries of neurocognitive testing, Set A and Set B, are ad-
ministered according to the schedule set out in Table 1,
which also outlines the neurocognitive domains measured
by each instrument. Neurocognitive Set A is paper based,
and consists of the Rey Auditory Verbal Learning Task [49],
Trail-making test [50, 51], and Digit-Span Sequencing [52].
Neurocognitive Set B is administered using an electronic
tablet device, and consists of Flankers task [53], Digit
Symbol coding [54] and Rapid Visual Information Pro-
cessing task [54].
Statistical analysis
Given the exploratory nature of the study, twenty partic-
ipants will provide sufficient proof of the safety of the
dose. While not powered to detect statistically significant
effect sizes, findings will inform a planned randomised
control trial of LDX for the treatment of methampheta-
mine dependence.
Descriptive statistics of proportion commenced on study
drug who complete the study; proportion who achieve
each dose; proportion who experience adverse event by
type, severity and dose. Tolerability of LDX will be de-
scribed using medians and interquartile ranges of TSQM
side-effects scores. Continuous and categorical primary
outcomes will be examined within a generalised linear
mixed model framework [55]. Secondary outcomes mea-
sures changes in MA use, other substance use, craving,
withdrawal, severity of dependence, risk behaviour scores
and neurocognition will be tested for statistical signifi-
cance using Wilcoxon rank-sum test for non-parametric
data. The estimation of magnitude of effects of LDX on
MA use will be calculated separately for those individuals
that have and have not been adherent to counselling
during the course of the study. Dose adequacy, medication
acceptability, and potential for non-prescription use will
be described using median scores and interquartile ranges
at each dose. Analysis of urine drug results will follow
established practice so that missing urine results are
assigned as being positive for methamphetamine and the
proportion of urines positive for methamphetamine will
be reported. Missing data will be imputed using multiple
imputation procedures.
Discussion
Research related to pharmacotherapy options for the
treatment of methamphetamine dependence has been
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often underpowered, with some concerns of under-dosing
also noted [6]. The publication of study protocols such as
this not only represents good clinical trial practice, but al-
lows for the sharing of methodology in phase 2 studies in
addiction pharmacotherapy research. Safety data for this
population are essential to ensure dosing at optimal levels
in larger scale trials. As abstinence from methampheta-
mine use for the period of the trial is not mandatory, the
safety data elicited from this trial may be applied to more
“real-world” scenarios, such as outpatient programs for
stimulant users. Limitations of the study include the lack
of a control group and the small sample size. While this is
typical of numbers required for safety data, it limits the
generalizability of the secondary efficacy measures. The
trial is open-label, and non-randomised and thus partici-
pants may be subject to expectancy effects. To mitigate
this, subjects and dispensing nurses are aware of the mini-
mum and maximum doses, but blinded to the dose and to
the escalation and de-escalation regimen. Though concur-
rent methamphetamine use is dependent on self-report, a
validated tool (the TLFB interview) is used to obtain this
data. Determining the safety and dose optimization of
LDX within the target population will provide valuable
data for phase 3 studies on the efficacy of LDX to treat
methamphetamine dependence.
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